Equities analysts expect that Omeros Co. (NASDAQ:OMER) will report earnings per share (EPS) of ($0.72) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Omeros’ earnings, with the lowest EPS estimate coming in at ($0.73) and the highest estimate coming in at ($0.70). Omeros reported earnings per share of ($0.07) during the same quarter last year, which would suggest a negative year-over-year growth rate of 928.6%. The company is scheduled to report its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Omeros will report full year earnings of ($2.67) per share for the current fiscal year, with EPS estimates ranging from ($2.71) to ($2.62). For the next year, analysts expect that the business will post earnings of ($1.13) per share, with EPS estimates ranging from ($2.04) to ($0.22). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Omeros.
Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter last year, the business earned ($0.33) earnings per share. The company’s quarterly revenue was down 90.1% on a year-over-year basis.
OMER has been the topic of a number of recent analyst reports. HC Wainwright set a $34.00 price target on shares of Omeros and gave the company a “buy” rating in a research report on Wednesday, July 18th. Seaport Global Securities initiated coverage on shares of Omeros in a research report on Thursday, July 12th. They set a “buy” rating and a $30.00 price target on the stock. ValuEngine raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Maxim Group set a $25.00 price target on shares of Omeros and gave the company a “buy” rating in a research report on Sunday, May 13th. Finally, Zacks Investment Research raised shares of Omeros from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Saturday, July 28th. One analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Omeros presently has an average rating of “Buy” and a consensus price target of $27.56.
OMER opened at $24.76 on Tuesday. The company has a debt-to-equity ratio of -2.31, a quick ratio of 3.94 and a current ratio of 3.95. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $26.97. The stock has a market cap of $1.29 billion, a P/E ratio of -31.34 and a beta of 3.84.
In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of Omeros stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $25.75, for a total value of $193,871.75. Following the sale, the vice president now owns 227,645 shares of the company’s stock, valued at $5,861,858.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Marcia S. Kelbon sold 40,723 shares of Omeros stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the sale, the vice president now directly owns 219,645 shares in the company, valued at approximately $4,735,546.20. The disclosure for this sale can be found here. Insiders have sold 52,529 shares of company stock worth $1,163,730 over the last three months. 12.10% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in OMER. BlueMountain Capital Management LLC bought a new stake in Omeros in the second quarter worth about $118,000. Claraphi Advisory Network LLC bought a new stake in Omeros in the first quarter worth about $134,000. Quad Cities Investment Group LLC bought a new stake in Omeros in the second quarter worth about $161,000. Belpointe Asset Management LLC bought a new stake in Omeros in the second quarter worth about $204,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Omeros in the first quarter worth about $229,000. 48.14% of the stock is currently owned by institutional investors and hedge funds.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.